Johnson & Johnson Other Income (Expense)

: $-4,000 Mil (TTM As of Sep. 2021)

View and export this data going back to 1944. Start your Free Trial

Johnson & Johnson's other income expense for the Johnson & Johnson's pretax income for the three months ended in Sep. 2021 was $-2,810 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2021 was $-4,000 Mil.

Johnson & Johnson Other Income (Expense) Historical Data

The historical data trend for Johnson & Johnson's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Other Income (Expense)

-730.00

-675.00

-2,782.00

-3,681.00

-3,327.00

Johnson & Johnson Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Other Income (Expense)																-1,406.00	-2,451.00	829.00	432.00	-2,810.00

Johnson & Johnson Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4,000 Mil.

Johnson & Johnson (NYSE:JNJ) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Johnson & Johnson Business Description

Industry

Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834

Comparable Companies

NYSE:PFE NYSE:MRK NYSE:ABBV NYSE:LLY NYSE:BMY NAS:AMGN NAS:GILD NYSE:AGN NAS:BIIB NAS:HZNP XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 FRA:A60 XTER:BAYN SHSE:600276 TSE:4568

Traded in Other Exchanges

JNJ:Peru JNJ:Mexico 0R34:UK JNJ:Germany JNJ:Chile JNJB34:Brazil JNJ:Austria JNJ:Argentina

Address

One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933

Website

http://www.jnj.com

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.

Executives

Weinberger Mark A	director	METLIFE, INC. 200 PARK AVENUE NEW YORK NY 10166
Hewson Marillyn A	director	C/O CARPENTER TECHNOLOGY CORPORATION PO BOX 14662 READING PA 19612-4662
Washington A. Eugene	director	ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wengel Kathryn E	officer: EVP, Chief GSC Officer	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Mcevoy Ashley	officer: EVP, WW Chair, Medical Devices	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Perez William D	director	PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: PEREZ WILLIAM D a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mongon Thibaut	officer: Exec VP, WW Chair, Consumer	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Stoffels Paulus	officer: Vice Chair, Exec Committee	ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Ullmann Michael H	officer: Exec VP, General Counsel	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Fasolo Peter	officer: Exec VP, Chief HR Officer	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Wolk Joseph J	officer: Exec VP, CFO	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Taubert Jennifer L	officer: EVP, WW Chair, Pharmaceuticals	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Sneed Michael E	officer: EVP, Global Corp Aff & COO	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Decker Robert J	officer: Controller, CAO	ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Gorsky Alex	director, officer: Chairman, CEO	JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933

Johnson & Johnson Headlines

From GuruFocus

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA� and AVEENO� Aerosol Sunscreen Products Due to the Presence of Benzene

By PRNewswire 07-14-2021

Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities

By PRNewswire 06-09-2021

Women Cancer Victims Opposed to Johnson & Johnson's 'Texas Two-Step' Bankruptcy Ploy Urge Passage of Reforms Introduced by Warren, Durbin, Nadler, Blumenthal, and Maloney

By PRNewswire 07-29-2021

Other Sources

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Valuation

Economic Indicators

By Country

Articles

Submit Articles

Johnson & Johnson Other Income (Expense)

Johnson & Johnson Other Income (Expense) Historical Data

Johnson & Johnson Other Income (Expense) Calculation

Johnson & Johnson Business Description

Johnson & Johnson Headlines

Yacktman Holding Johnson & Johnson Rises on 2nd-Quarter Earnings Beat

Johnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2021

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA� and AVEENO� Aerosol Sunscreen Products Due to the Presence of Benzene

Portnoy Law: Lawsuit Filed On Behalf of Johnson & Johnson Consumer, Inc. Investors

Johnson & Johnson to Host Live ESG Investor Update Webcast

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa

Lawyers for Ovarian Cancer Victims Call on Regulators to Stop 'Contemptible' Johnson & Johnson Bankruptcy Plan

Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities

Women Cancer Victims Opposed to Johnson & Johnson's 'Texas Two-Step' Bankruptcy Ploy Urge Passage of Reforms Introduced by Warren, Durbin, Nadler, Blumenthal, and Maloney

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1

Worries About the Delta Variant Could Be Overdone Based on Clues From These Healthcare Giants

Pharma Stock Roundup: FDA Nod for MRK, PFE Products & New Use of LLY, GSK Drugs

FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

Pfizer's (PFE) Tick-Borne Encephalitis Vaccine Gets FDA Nod

Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track

Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?

Pfizer (PFE)/BioNTech Give First COVID Jab Booster Data to FDA

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

J&J (JNJ) CEO Alex Gorsky to Resign, Joaquin Duato to Succeed